| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/29/2007 | CN101023975A Composition containing effective parts of astragalus root and Acanthopanx senticosusharm and its use thereof |
| 08/29/2007 | CN101023960A Preparation of anti-virus, anti-tumor medicine of nano methanaminium containing earopium |
| 08/29/2007 | CN101023950A Allopurinol sodium sterilzed powder for injection and preparing method |
| 08/29/2007 | CN101023945A Use of non-periphery substituted phthalocyaniu metal complex |
| 08/29/2007 | CN101023941A Docetaxel injecta and preparing method |
| 08/29/2007 | CN101023940A Medicine composition of Taxane compounds, preparing method and use |
| 08/29/2007 | CN101023931A Anti-cancer composition containing blood-vessel inhibitor and taxanes |
| 08/29/2007 | CN101023930A Anti-cancer composition carried with new-born blood-vessel inhibiting agent and alkalating agent |
| 08/29/2007 | CN101023928A Slow-release injecta containing new-born blood-vessel-inhibiting agent and platinum-like compounds |
| 08/29/2007 | CN101023925A Anti-cancer composition containing chemical-therapy synergistic agent |
| 08/29/2007 | CN101023924A Entity-tumor-resistant slow-release agent containing glucocorticoid hormone |
| 08/29/2007 | CN101023923A Anti-cancer slow-release agent containing glucocorticoid hormone |
| 08/29/2007 | CN101023922A Anti-cancer slow-release agent carried with glucocorticoid hormone and chemical therapy medicine |
| 08/29/2007 | CN101023920A Entity-tumor-resistant medicine composition |
| 08/29/2007 | CN101023919A Entity-tumor-resistant slow-release agent |
| 08/29/2007 | CN101023918A Anti-cancer medicine composition carried with platinum-like compounds and glucocorticoid hormone |
| 08/29/2007 | CN101023893A Endoluminal device for treating disease of aneurysm and combination of drugs |
| 08/29/2007 | CN101023794A Method for sweet potato meal fiber tablets |
| 08/29/2007 | CN100334094C Antitumoral analogs |
| 08/29/2007 | CN100334077C Benzimidazole derivatives and their use as GNRH antagonists |
| 08/29/2007 | CN100333797C Novel use of tumor treating of recombinant adenoviral p53 products |
| 08/29/2007 | CN100333794C Adjuvanted genetic vaccines |
| 08/29/2007 | CN100333790C The pharmaceutical applications for combination of drugs with interleukin-2 |
| 08/29/2007 | CN100333788C Tumor cell apoptosis accelerating medicine |
| 08/29/2007 | CN100333787C YG and YGG used as maintenance and improvement of immunoreaction |
| 08/29/2007 | CN100333753C Extraction technology of plant total alkaloid extract having anti tumour action and its preparation |
| 08/29/2007 | CN100333736C Medication for treating ascites of liver, cirrhosis of liver and liver cancer in early stage |
| 08/29/2007 | CN100333734C Supramolecular extractive of creat, preparation method and application |
| 08/29/2007 | CN100333730C Intravenous injection of antitumor compound nobilisideA and monoacetylated liposome and its prepn. |
| 08/29/2007 | CN100333726C Disintegration piece taken through oral cavity containing Gimeracil and Oteracil Potassium with fluorine being added |
| 08/29/2007 | CN100333725C New usage of STI-571 in application for treating acute leukaemia in marrow M2b type |
| 08/28/2007 | US7262302 Antiinflammatory action; rheumatoid arthritis |
| 08/28/2007 | US7262286 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 08/28/2007 | US7262277 Antagonistic anti-hFAS ligand human antibodies and fragments thereof |
| 08/28/2007 | US7262267 Polypeptide mediating cell permeability |
| 08/28/2007 | US7262215 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors |
| 08/28/2007 | US7262213 Administering (-)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (-)-OddC) for therapy of cancer such as non-small cell lung cancer, colon cancer, breast cancer, prostate cancer, ovarian cancer, leukemia, CNS cancer, melanoma, renal cancer, and lymphoma cancer |
| 08/28/2007 | US7262211 Activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have at a group having a guanidino moiety or derivative thereof. These compounds are useful for |
| 08/28/2007 | US7262203 For therapy of hyperproliferative diseases such as cancer or retinopathy; pazopanib and salts |
| 08/28/2007 | US7262202 2-substituted 4-pyrrolyl-pyrimidines, e.g., 2-[N-(phenyl)]-4-(2,4-dimethylpyrrol-3-yl)pyrimidineamines in which the phenyl group is 2-, 3-, 4-or 5-substituted by at least one of F, NH2, NO2, OH, Cl, Br, I, CN, CH2OH, CF3 or OMe. |
| 08/28/2007 | US7262201 Quinazoline derivatives |
| 08/28/2007 | US7262199 Tyrosine kinase inhibitors |
| 08/28/2007 | US7262193 Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient |
| 08/28/2007 | US7262187 Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor |
| 08/28/2007 | US7262186 Kinesin spindle protein inhibitor; antiproliferative agents; anticancer agents; 4-(2,5-difluorophenyl0-N-3-fluoropyrrolidin-3-yl)-2-hydroxymethyl-2-phenyl-2,5-dihydro-1N-pyrrol-1-carboxamide |
| 08/28/2007 | US7262177 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use |
| 08/28/2007 | US7262175 Anticancer agents; blood disorders |
| 08/28/2007 | US7262173 Chemosensitizing with liposomes containing oligonucleotides |
| 08/28/2007 | US7262165 Aqueous preparation containing oligopeptides and etherified cyclodextrin |
| 08/28/2007 | US7262164 Polymeric thiol-linked prodrugs employing benzyl elimination systems |
| 08/28/2007 | US7262052 DNA sequence that encodes a polypeptide that is a voltage activated calcium channel alpha 2 delta -C subunit |
| 08/28/2007 | US7262044 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 08/28/2007 | US7261906 Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition |
| 08/28/2007 | CA2504078C Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| 08/28/2007 | CA2265874C Condensed n-acylindoles as antitumor agents |
| 08/28/2007 | CA2230960C Piperazine derivatives and process for the preparation thereof |
| 08/24/2007 | CA2537669A1 Inhibitors of nucleoside phosphorylases and nucleosidases for treating cancer |
| 08/23/2007 | WO2007095632A1 Crystalline forms of (3r,4r)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methol]piperidin-3-ol |
| 08/23/2007 | WO2007095628A1 Pyrazoloquinolones are potent parp inhibitors |
| 08/23/2007 | WO2007095588A1 Pi-3 kinase inhibitors and methods of their use |
| 08/23/2007 | WO2007095583A2 Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin |
| 08/23/2007 | WO2007095223A2 Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases |
| 08/23/2007 | WO2007095124A2 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
| 08/23/2007 | WO2007094495A2 Novel anticancer cathepsin preparation and anticancer agent for combination therapy against cancer using the same |
| 08/23/2007 | WO2007094462A1 Non-human animal having modified genome or offspring thereof |
| 08/23/2007 | WO2007094430A1 Cancer inhibitor, cancer inhibitor-containing product and process for producing cancer inhibitor |
| 08/23/2007 | WO2007094193A1 Anti-angiogenic agent, prophylactic or therapeutic agent for disease accompanied by angiogenesis, and food |
| 08/23/2007 | WO2007094027A2 Methods for the diagnosis of proliferative and/or conformational diseases |
| 08/23/2007 | WO2007094026A1 Prophylactic and/or therapeutic treatment of proliferative and conformational diseases |
| 08/23/2007 | WO2007093873A1 Bis-pyrr0l0[2,l-c] [1, 4] benzodiazepine- anthraquinone conjugates as antitumour agents and a process for the preparation thereof |
| 08/23/2007 | WO2007093827A1 Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors |
| 08/23/2007 | WO2007093806A1 Dissolution aids for oral peptide delivery comprising a biguanide |
| 08/23/2007 | WO2007093630A1 Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| 08/23/2007 | WO2007093519A2 Ibandronate regimen for treating metastatic bone pain |
| 08/23/2007 | WO2007093036A1 Use of local immune suppression to enhance oncolytic viral therapy |
| 08/23/2007 | WO2007093008A1 Antibodies to insulin-like growth factor i receptor |
| 08/23/2007 | WO2007092978A1 Use of gallium(iii) complexes for the treatment of melanomas |
| 08/23/2007 | WO2007079203A3 Treatment for cutaneous t cell lymphoma |
| 08/23/2007 | WO2007079202A3 Treatment for acute lymhoblastic leukemia |
| 08/23/2007 | WO2007076085A3 Fused pyrimidones and thiopyrimidones, and uses thereof |
| 08/23/2007 | WO2007073518A9 Compounds and methods for thiol-containing compound efflux and cancer treatment |
| 08/23/2007 | WO2007069272A3 Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| 08/23/2007 | WO2007065664A3 Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors |
| 08/23/2007 | WO2007064448A3 Cancer treatment using fts and 2-deoxyglucose |
| 08/23/2007 | WO2007059257A3 N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| 08/23/2007 | WO2007020459A3 Antisense oligonucleotides against protein kinase isoforms alpha, beta and gamma |
| 08/23/2007 | WO2006120568A3 Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone |
| 08/23/2007 | WO2006097337A3 11β-HYDROXYSTEROID DEHYDROGENASES |
| 08/23/2007 | WO2006036269A3 Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof |
| 08/23/2007 | WO2005035003A9 Compositions and methods for increasing drug efficiency |
| 08/23/2007 | WO2002097035A3 Secreted proteins |
| 08/23/2007 | US20070197829 Process for the synthesis and crystalline form agomelatine |
| 08/23/2007 | US20070197775 Cytotoxic agents comprising taxanes and their therapeutic use |
| 08/23/2007 | US20070197660 Compounds for modulating cell proliferation |
| 08/23/2007 | US20070197644 Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 08/23/2007 | US20070197611 Fermentative preparation process for and crystal forms of cytostatics |
| 08/23/2007 | US20070197551 such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome |
| 08/23/2007 | US20070197547 4-(1-piperazinyl)-2(1H)-quinolone and 4-(1-piperazinyl)quinoline derivatives, e.g., 4-(1-piperazinyl)-1-methyl-3-nitro-2(1H)-quinolone |
| 08/23/2007 | US20070197534 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide; for treating cancer; radiosensitising in a subject tumor cells of solid tumors in hypoxic conditions |
| 08/23/2007 | US20070197517 Combination therapy for hyperproliferative disease |